Package Leaflet: Information for the User
Infanrix-IPV, injectable suspension in a pre-filled syringe
Diphtheria, tetanus, pertussis (acellular component) and poliomyelitis (inactivated) (adsorbed) vaccine
Read all of this leaflet carefully before your child starts receiving this vaccine because it contains important information for you.
|
Contents of the package leaflet
Infanrix-IPV is a vaccine used as a booster dose to protect your child against 4 diseases:
Infanrix-IPV is for children from 16 months to 13 years (inclusive). It is not indicated for people over 14 years old.
How Infanrix-IPV works
Infanrix-IPV should not be administered
Infanrix-IPV should not be administered if any of the above situations apply to your child. If you are not sure, talk to your doctor or pharmacist before your child receives Infanrix-IPV.
Warnings and precautions
Consult your doctor or pharmacist before your child receives Infanrix-IPV if:
Before or after any injection, fainting (especially in adolescents) may occur, so you should inform your doctor or nurse if your child has fainted after receiving an injection in the past.
If any of the above situations apply to your child (or you are not sure), talk to your doctor or pharmacist before your child receives Infanrix-IPV.
Other medicines and Infanrix-IPV
Tell your doctor or pharmacist if your child is using, has recently used, or might use any other medicines.
In particular, tell your doctor or pharmacist if your child is using any of the following:
Pregnancy and breastfeeding
It is unlikely that Infanrix-IPV will be administered to pregnant or breastfeeding women. This is because the vaccine is only indicated for children from 16 months to 13 years (inclusive).
Administration of this vaccine during pregnancy or breastfeeding is not recommended.
Consult your doctor or pharmacist before using any medicine.
Driving and using machines
It is unlikely that Infanrix-IPV will be administered to people who drive or use tools or machines. This is because the vaccine is only indicated for children from 16 months to 13 years (inclusive).
Your child may feel drowsy after vaccination. If this happens, your child should not drive, ride a bicycle, or use tools or machines.
Infanrix-IPV contains neomycin, polymyxin (antibiotics), para-aminobenzoic acid, phenylalanine, sodium, potassium, and formaldehyde.Infanrix-IPV should not be administered to your child if they are allergic to any of these components. Please consult your doctor if your child has had an allergic reaction to these components.
Infanrix-IPV contains para-aminobenzoic acid. It can cause allergic reactions (possibly delayed) and, exceptionally, bronchospasm.
This vaccine contains 0.036 micrograms of phenylalanine per dose. Phenylalanine may be harmful in case of phenylketonuria (PKU), a rare genetic disease in which phenylalanine accumulates because the body is unable to eliminate it properly.
This vaccine contains less than 1 mmol of sodium (23 mg) per dose; it is essentially "sodium-free".
This vaccine contains potassium, less than 1 mmol (39 mg) per dose; it is essentially "potassium-free".
When the vaccine is administered
How Infanrix-IPV is administered
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. With this vaccine, the following side effects can occur:
Allergic reactions
If your child has an allergic reaction, go to a doctor immediately. The signs may include:
These signs usually start soon after receiving the injection. Take your child to the doctor immediately if they appear after leaving the clinic. Allergic reactions are very rare (less than 1 in 10,000 doses of vaccine).
Consult your doctor immediately if your child has any of the following serious side effects:
Consult your doctor immediately if you notice any of the above situations. These side effects have occurred with other pertussis vaccines. They usually appear within 2 or 3 days of vaccination.
Other side effects include:
Very common(may affect more than 1 in 10 doses of the vaccine): feeling drowsy, headache, loss of appetite, elevated temperature of 38°C or more, pain, redness, and swelling at the injection site, abnormal crying, feeling irritable or restless.
Common(may affect up to 1 in 10 doses of the vaccine): diarrhea, nausea, vomiting, elevated temperature of 39.5°C or more, feeling unwell, nodular rash at the injection site, feeling weak.
Uncommon(may affect up to 1 in 100 doses of the vaccine): skin allergies or rashes.
Rare(may affect up to 1 in 1,000 doses of the vaccine): swelling of the lymph nodes in the neck, armpits, and groin (lymphadenopathy), cough or chest infection (bronchitis), itching, nodular rash (urticaria).
Very rare(may affect up to 1 in 10,000 doses of the vaccine): bleeding or bruising more easily than normal (thrombocytopenia), temporary stop in breathing (apnea), inflammation of the face, lips, mouth, tongue, or throat, which can cause difficulty swallowing or breathing (angioedema), blisters at the injection site.
Booster doses of Infanrix-IPV may increase the risk of reactions at the injection site. Some of these reactions can affect the entire arm or leg where the injection was given. These reactions usually start 48 hours after the injection and disappear within 4 days.
Reporting of side effects
If your child experiences any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website (http://www.aemps.gob.es/). By reporting side effects, you can help provide more information on the safety of this medicine.
Composition of Infanrix-IPV
Diphtheria toxoid1 at least 30 IU
Tetanus toxoid1 at least 40 IU
Bordetella pertussisantigens
Pertussis toxoid1 25 micrograms
Filamentous hemagglutinin1 25 micrograms
Pertactin1 8 micrograms
Inactivated poliovirus2
Type 1 (Mahoney strain) 40 D-antigen units
Type 2 (MEF-1 strain) 8 D-antigen units
Type 3 (Saukett strain) 32 D-antigen units
1 adsorbed on hydrated aluminum hydroxide 0.5 milligrams Al3+
2 propagated in VERO cells
Aluminum hydroxide is included in this vaccine as an adjuvant. Adjuvants are substances present in some vaccines to accelerate, enhance, or prolong the protective effects of the vaccine.
Appearance of the product and package contents
Marketing authorization holder and manufacturer
Marketing authorization holder
GlaxoSmithKline, S.A.
P.T.M. C/ Severo Ochoa, 2
28760 Tres Cantos (Madrid)
Spain
Tel: +34 900 202 700
es-ci@gsk.com
This medicine is authorized in the Member States of the European Economic Area under the following names:
Greece, France, Portugal, Cyprus: InfanrixTetra
Czech Republic, Estonia, Latvia, Lithuania, Norway, Slovakia, Sweden: Infanrix Polio
Finland: Infanrix-Polio
Poland, Spain: Infanrix-IPV
Hungary: Infanrix IPV
Ireland: IPV Infanrix
Italy: PolioInfanrix
Date of last revision of this leaflet:April 2023
Other sources of information
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) (http://www.aemps.gob.es/).
---------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Once stored, a white deposit and a clear supernatant may be observed. This is not a sign of deterioration.
The syringe should be shaken well to obtain a white, turbid, and homogeneous suspension.
The suspension should be visually examined for any foreign particles and/or changes in physical appearance. If any of these circumstances are observed, discard the vaccine.
Instructions for the pre-filled syringe
Hold the syringe by the body, not by the plunger. Unscrew the syringe cap by turning it counterclockwise. | |
To insert the needle, connect the base to the luer-lock adapter and turn it a quarter turn clockwise until it clicks. Do not pull the plunger out of the syringe body. If this happens, do not administer the vaccine. |
Disposal of waste
Disposal of unused medicine and all materials that have come into contact with it will be carried out in accordance with local regulations.